- Home
- RPD vs HRMY Comparison
RPD vs HRMY Comparison
Compare RPD & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPD
- HRMY
- Stock Information
- Founded
- RPD 2000
- HRMY 2017
- Country
- RPD United States
- HRMY United States
- Employees
- RPD N/A
- HRMY N/A
- Industry
- RPD Computer Software: Prepackaged Software
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- RPD Technology
- HRMY Health Care
- Exchange
- RPD Nasdaq
- HRMY Nasdaq
- Market Cap
- RPD 2.1B
- HRMY 1.9B
- IPO Year
- RPD 2015
- HRMY 2020
- Fundamental
- Price
- RPD $41.31
- HRMY $34.24
- Analyst Decision
- RPD Buy
- HRMY Buy
- Analyst Count
- RPD 17
- HRMY 10
- Target Price
- RPD $45.25
- HRMY $49.80
- AVG Volume (30 Days)
- RPD 756.5K
- HRMY 431.7K
- Earning Date
- RPD 02-05-2025
- HRMY 10-29-2024
- Dividend Yield
- RPD N/A
- HRMY N/A
- EPS Growth
- RPD N/A
- HRMY N/A
- EPS
- RPD 0.66
- HRMY 2.11
- Revenue
- RPD $833,014,000.00
- HRMY $681,879,000.00
- Revenue This Year
- RPD $9.10
- HRMY $24.79
- Revenue Next Year
- RPD $5.46
- HRMY $17.98
- P/E Ratio
- RPD $59.15
- HRMY $15.70
- Revenue Growth
- RPD 10.05
- HRMY 25.83
- 52 Week Low
- RPD $32.95
- HRMY $28.14
- 52 Week High
- RPD $61.88
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- RPD 45.14
- HRMY 52.28
- Support Level
- RPD $38.54
- HRMY $31.50
- Resistance Level
- RPD $44.47
- HRMY $35.99
- Average True Range (ATR)
- RPD 1.08
- HRMY 1.16
- MACD
- RPD -0.45
- HRMY 0.03
- Stochastic Oscillator
- RPD 29.57
- HRMY 59.69
About RPD Rapid7 Inc.
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.